What is the 13F Pro Quality Score for WHWK?

13F Pro ranks Whitehawk Therapeutics, Inc. (WHWK) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View WHWK's current score at https://13fpro.ai/company/WHWK (free sign-up required for the full ranking).

Which hedge funds own the most WHWK stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of WHWK include Yu Fan, ACUTA CAPITAL PARTNERS,, QVT Financial. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/WHWK as soon as new 13F filings post.

Where does 13F Pro source WHWK data?

All Whitehawk Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Whitehawk Therapeutics, Inc. files with the SEC under CIK 1422142. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is WHWK in?

Whitehawk Therapeutics, Inc. (WHWK) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is WHWK research updated on 13F Pro?

WHWK's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Whitehawk Therapeutics, Inc.(WHWK)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1422142 WHWK stock profile & AI dashboard →

13F Pro Quality Score

26.4/100

Rank #2,729 of 3,064 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

30.0/100

Profitability

30.0/100

Balance Sheet

3.3/100

Earnings Quality

16.2/100

Free Cash Flow

30.0/100

Institutional Flow

66.5/100

Revenue Scale

30.0/100

Dilution Risk

2.1/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why WHWK Scores 26/100

exact factor attribution · 2026-08-23

WHWK's composite is held back by capital efficiency and revenue growth. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Institutional flow

+0.8 pts

67th pct

Earnings growth

-1.0 pts

30th pct

Shareholder dilution

-2.4 pts

2th pct

Profitability

-3.0 pts

30th pct

Free cash flow

-3.0 pts

30th pct

Scale

-3.0 pts

30th pct

Earnings quality

-3.4 pts

16th pct

Revenue growth

-4.0 pts

30th pct

Capital efficiency

-4.7 pts

3th pct

Latest change (2026-08-06): 10 → 27 · ↓ Capital efficiency 15→5

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

Unusual Activity in WHWK

Events flagged as statistical outliers against WHWK's own multi-year baseline — not fixed dollar thresholds.

Score shock2026-08-06
WHWK quality score jumped 17 points (10→27) on a new filing
View source filing →

WHWK Stock Analysis & AI Quality Score

Data updated 2026-08-23

AI stock analysis and institutional research for Whitehawk Therapeutics, Inc. (WHWK), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores WHWK at 26.4/100 on a 32-signal composite quality model, placing it at rank #2,729 of 3,064 stocks — the bottom half of the AI-ranked universe. Areas of concern include balance sheet strength (3.3) and earnings quality (16.2), which score below median versus the broader universe. Shareholder dilution risk is elevated at 2.1/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Whitehawk Therapeutics, Inc. reports net income of $-16.6M, free cash flow of $-14.5M. Top institutional holders of WHWK by reported 13-F value include Yu Fan, ACUTA CAPITAL PARTNERS, QVT Financial, based on the most recent SEC filings. WHWK trades on the Nasdaq exchange and files with the SEC under CIK 1422142. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate WHWK daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Whitehawk Therapeutics, Inc. directly from SEC EDGAR. Whitehawk Therapeutics, Inc.'s 13F Pro composite quality score has ranged between 9 and 60 since 2024, currently 26.4 — a stable long-term trajectory across 50 quarterly and live scoring snapshots.

Revenue

Q2 2026

$0.00

Net Income

Q2 2026

$-16.6M

Free Cash Flow

Q2 2026

$-14.5M

ROIC

Q2 2026

-39.6%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

-72.5% YoY

$7.1MFY 2025

FY22 $15.2MFY23 $24.4MFY24 $26.0MFY25 $7.1M

Net Income

+67.7% YoY

$-20.6MFY 2025

FY22 $-60.5MFY23 $-65.8MFY24 $-63.7MFY25 $-20.6M

Operating Income

-69.6% YoY

$-114.4MFY 2025

FY22 $-62.7MFY23 $-71.9MFY24 $-67.5MFY25 $-114.4M

EPS (Diluted)

+72.0% YoY

$-0.33FY 2025

FY22 $-1.34FY23 $-1.22FY24 $-1.18FY25 $-0.33

Total Assets

+114.5% YoY

$150.8MFY 2025

FY22 $184.2MFY23 $132.4MFY24 $70.3MFY25 $150.8M

Op. Cash Flow

-63.6% YoY

$-97.4MFY 2025

FY22 $-49.6MFY23 $-59.7MFY24 $-59.5MFY25 $-97.4M

Free Cash Flow

-60.1% YoY

$-98.0MFY 2025

FY22 $-50.1MFY23 $-63.6MFY24 $-61.2MFY25 $-98.0M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$7.1M -72.5%	$26.0M +6.7%	$24.4M +60.1%	$15.2M +8.7%	$14.0M +0.0%	$14.0M
Net Income	$-20.6M +67.7%	$-63.7M +3.2%	$-65.8M -8.7%	$-60.5M +45.0%	$-110.1M -3065.3%	$-3.5M
Operating Income	$-114.4M -69.6%	$-67.5M +6.2%	$-71.9M -14.8%	$-62.7M +43.6%	$-111.2M -4263.2%	$-2.5M
EPS (Diluted)	$-0.33 +72.0%	$-1.18 +3.3%	$-1.22 +9.3%	$-1.34 +78.3%	$-6.21	—
Total Assets	$150.8M +114.5%	$70.3M -46.9%	$132.4M -28.1%	$184.2M +16.7%	$157.9M +738.8%	$18.8M
Operating Cash Flow	$-97.4M -63.6%	$-59.5M +0.2%	$-59.7M -20.2%	$-49.6M -121.4%	$-22.4M -76.5%	$-12.7M
Free Cash Flow	$-98.0M -60.1%	$-61.2M +3.8%	$-63.6M -27.1%	$-50.1M -122.9%	$-22.5M -76.6%	$-12.7M

Get alerted when WHWK's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Whitehawk Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of WHWK

Yu Fan
$22.3M4,861,314 sh
ACUTA CAPITAL PARTNERS, LLC
$21.5M4,685,912 sh
QVT Financial LP
$21.1M4,615,709 sh
SUVRETTA CAPITAL MANAGEMENT, LLC
$19.7M4,300,000 sh
ORBIMED ADVISORS LLC
$18.0M3,934,296 sh
Avoro Capital Advisors LLC
$13.1M2,849,402 sh
Siren, L.L.C.
$10.7M2,337,102 sh
KVP Capital Advisors, LP
$9.9M2,165,997 sh
BlackRock, Inc.
$8.8M1,922,828 sh
VANGUARD CAPITAL MANAGEMENT LLC
$6.4M1,388,561 sh

Fund	Value	Shares
Yu Fan	$22.3M	4,861,314
ACUTA CAPITAL PARTNERS, LLC	$21.5M	4,685,912
QVT Financial LP	$21.1M	4,615,709
SUVRETTA CAPITAL MANAGEMENT, LLC	$19.7M	4,300,000
ORBIMED ADVISORS LLC	$18.0M	3,934,296
Avoro Capital Advisors LLC	$13.1M	2,849,402
Siren, L.L.C.	$10.7M	2,337,102
KVP Capital Advisors, LP	$9.9M	2,165,997
BlackRock, Inc.	$8.8M	1,922,828
VANGUARD CAPITAL MANAGEMENT LLC	$6.4M	1,388,561

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put WHWK on your watchlist

Track score changes the day Whitehawk Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is WHWK a good stock to buy?

13F Pro's AI-powered analysis of Whitehawk Therapeutics, Inc. (WHWK) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for WHWK are available on the WHWK stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. WHWK is classified as a small company.

Which hedge funds own WHWK?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling WHWK. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Whitehawk Therapeutics, Inc.'s investment landscape.